- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT07951762
A Phase I/II Clinical Trial of SYS6043 Monotherapy or SYS6043 Combined With PD-1/VEGF Bispecific Antibody ± Chemotherapy in the Treatment of Advanced Solid Tumors.
An Open-label, Multicenter Phase I/II Clinical Trial Evaluating the Safety, Tolerability, Pharmacokinetic Characteristics, and Preliminary Efficacy of SYS6043 Monotherapy or SYS6043 Combined With PD-1/VEGF Bispecific Antibody ± Chemotherapy in Patients With Advanced Solid Tumors.
This is a multicenter phase 1/2 clinical study to evaluate the efficacy and safety of SYS6043 monotherapy or SYS6043 combined with PD-1/VEGF bispecific antibody ± chemotherapy in patients with advanced solid tumors.
Studieöversikt
Status
Betingelser
Detaljerad beskrivning
The Phase I study is a a dose-escalation study, comprises dose escalation for the doublet regimen and dose escalation for the triplet regimen. The Phase II study isa cohort expansion study.
Phase I: the dose escalation use a 3+3 design. The doublet regimen consists of SYS6043 + PD-1/VEGF bispecific antibody. The triplet regimen consists of SYS6043 combined with PD-1/VEGF bispecific antibody ± chemotherapy.
The Phase II study will be conducted as an expansion in 6 cohorts, with indications including triple-negative breast cancer, small cell lung cancer, non-small cell lung cancer, etc.
Studietyp
Inskrivning (Beräknad)
Fas
- Fas 2
- Fas 1
Kontakter och platser
Studiekontakt
- Namn: Jian Zhang
- Telefonnummer: 021-64175590
- E-post: syner2000@163.com
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Beskrivning
Inclusion Criteria:
- Be able to understand and voluntarily sign and datethe written ICF prior to any trial-related procedure;
- Age 18-75 (inclusive) years;
- Histologically or cytologically confirmed advanced/unresectable or metastatic solid tumors(specific cohort requirements apply, including TNBC, SCLC, and driver-gene negative NSCLC based on UICC/AJCC 8th edition staging);
- Dose escalation phase: evaluable lesions per RECIST v1.1. Dose expansion phase: at least one extracranial measurable lesion per RECIST v1.1. Lesions previously treated with radiotherapy or other local therapy may not be selected as target lesions unless there is clear evidence of progression.
- Qualified archived or fresh tumor tissue samples must be provided; participants who cannot provide tumor samples or whose samples are insufficient may be enrolled based on individual circumstances.
- Eastern Cooperative Oncology Group (ECOG) performance status score: 0-1;
- Adequate organ and bone marrow function within 7 days prior to the first dose, as defined below.
- Life expectancy ≥ 3 months;
- Female participants of childbearing age must have a negative serum pregnancy test within 7 days before dosing. Male and female participants of reproductive potential must agree to use adequate contraception during the study and for at least 7 months after the last dose of the investigational product; during this period, female participants must not be breastfeeding, male participants must not freeze or donate sperm, and female participants must not donate eggs or undergo egg retrieval for personal use.
Exclusion Criteria:
- Combined SCLC (i.e., mixed large cell carcinoma, squamous cell carcinoma, spindle/pleomorphic and/or large cell components) and transformed SCLC.
- Prior history of CTCAE grade ≥3 immune-related adverse events (irAEs) during treatment with anti-PD-(L)1 or other immune checkpoint inhibitors, immune checkpoint agonists, immune cell therapy, or other therapies targeting tumor immune mechanisms, except for endocrine disorders such as hyperglycemia or hypothyroidism that have recovered to grade ≤2.
- Prior treatment with B7-H3-targeted therapies (including antibodies, antibody-drug conjugates [ADCs], chimeric antigen receptor T-cell [CAR-T] therapies, and other agents).
- Prior treatment with a topoisomerase I inhibitor antibody-drug conjugate or a topoisomerase I inhibitor.
- Toxicities from prior antitumor therapy have not resolved to CTCAE grade ≤1 or to the levels specified in the inclusion/exclusion criteria (except alopecia and hyperpigmentation).
- History of underlying pulmonary disease, including but not limited to severe asthma, severe COPD, restrictive lung disease, and other clinically significant pulmonary impairment or requirement for supplemental oxygen.
Studieplan
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Behandling
- Tilldelning: Icke-randomiserad
- Interventionsmodell: Parallellt uppdrag
- Maskning: Ingen (Open Label)
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
|---|---|
|
Experimentell: SYS6043+PD-1/VEGF bispecific antibody
|
SYS6043: IV PD-1/VEGF bispecific antibody: IV |
|
Experimentell: SYS6043 combined with PD-1/VEGF bispecific antibody +chemotherapy.
|
SYS6043: IV PD-1/VEGF bispecific antibody: IV Chemotherapy: cisplatin or carboplatin, IV |
|
Experimentell: SYS6043 monotherapy
|
SYS6043: IV |
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Phase I: Incidences of AEs
Tidsram: From the signing of the informed consent form until 90 days after the last dose.
|
From the signing of the informed consent form until 90 days after the last dose.
|
|
|
Phase I: DLT
Tidsram: 21 days
|
Dose-limiting toxicity |
21 days
|
|
Phase I: MTD/RP2D
Tidsram: After phase I dose escalation stage. Approximately 4 months.
|
Maximum Tolerated Dose/ Recommended Phase II Dose |
After phase I dose escalation stage. Approximately 4 months.
|
|
Phase II: ORR
Tidsram: Up to 2 years
|
Objective response rate |
Up to 2 years
|
Sekundära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Phase I: ORR
Tidsram: Up to 2 years
|
Objective response rate |
Up to 2 years
|
|
Phase I:DCR
Tidsram: Up to 2 years
|
Disease control rate |
Up to 2 years
|
|
Phase I:DOR
Tidsram: Up to 2 years
|
Duration of response |
Up to 2 years
|
|
Phase I: TTR
Tidsram: Up to 2 years
|
Time to Response |
Up to 2 years
|
|
Phase I: PFS
Tidsram: Up to 2 years
|
Progression free survival |
Up to 2 years
|
|
Phase I:OS
Tidsram: Up to 3 years
|
Overall survival |
Up to 3 years
|
|
Phase I:Plasma concentrations of SYS6043, total antibody, and free JS-1.
Tidsram: Up to 2 years
|
Up to 2 years
|
|
|
Phase I:Incidence of anti-drug antibodies (ADAs) and neutralizing antibodies (NAbs) for SYS6043.
Tidsram: Up to 2 years
|
Up to 2 years
|
|
|
Phase I:Expression levels of proteins such as B7-H3 and PD-L1 in tumor tissue.
Tidsram: Up to 2 years
|
Up to 2 years
|
|
|
Phase II:DCR
Tidsram: Up to 2 years
|
Disease control rate |
Up to 2 years
|
|
Phase II:DOR
Tidsram: Up to 2 years
|
Duration of response |
Up to 2 years
|
|
Phase II: TTR
Tidsram: Up to 2 years
|
Time to Response |
Up to 2 years
|
|
Phase II: PFS
Tidsram: Up to 2 years
|
Progression free survival |
Up to 2 years
|
|
Phase II:OS
Tidsram: Up to 3 years
|
Up to 3 years
|
|
|
Title: Phase II: Incidences of AEs
Tidsram: From the signing of the informed consent form until 90 days after the last dose.
|
Overall survival |
From the signing of the informed consent form until 90 days after the last dose.
|
|
Phase II:Plasma concentrations of SYS6043, total antibody, and free JS-1.
Tidsram: Up to 2 years
|
Up to 2 years
|
|
|
Phase II:Incidence of anti-drug antibodies (ADAs) and neutralizing antibodies (NAbs) for SYS6043.
Tidsram: Up to 2 years
|
Up to 2 years
|
|
|
Phase II:Expression levels of proteins such as B7-H3 and PD-L1 in tumor tissue.
Tidsram: Up to 2 years
|
Up to 2 years
|
Samarbetspartners och utredare
Studieavstämningsdatum
Studera stora datum
Studiestart (Beräknad)
Primärt slutförande (Beräknad)
Avslutad studie (Beräknad)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Faktisk)
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Andra studie-ID-nummer
- SYS6043-005
Läkemedels- och apparatinformation, studiedokument
Studerar en amerikansk FDA-reglerad läkemedelsprodukt
Studerar en amerikansk FDA-reglerad produktprodukt
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .